Trial Profile
A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Vistakon Pharmaceuticals
- 21 Jun 2014 New trial record